Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

GlaxoSmithKline Partners With Texas A&M And State Officials On $91 Million Vaccine Manufacturing Facility

03/26/2013
GlaxoSmithKline, Texas A&M and state officials formed “a major partnership” that will create a $91 million state-of-the-art influenza-vaccine manufacturing facility” in College Station, Texas. The facility will anchor the Texas A&M Center for Innovation in Advanced Development and Manufacturing, which will play a major role in securing the nation from bio-terrorism and global pandemic through the rapid development and manufacturing of vaccines to protect human life, officials said.

"GSK is privileged to deepen our commitment to U.S. public health, as part of this unprecedented public-private collaboration to protect against pandemics and bio-threats," Senior Vice President Antoon Loomans. "In Texas A&M we have found a partner with a rich tradition of service, and with pioneering technologies that will benefit the entire pharmaceutical industry in making vaccines available and accessible to all in need.

"Over the past decade, we have invested in innovative programs to prioritize research in our state at both our universities and in the private sector. This combined with Texas' workforce and business climate have made us a leader in high-tech innovation, research, development and commercialization," Gov. Rick Perry said. "Not only will this center keep Americans safer from epidemic, it will bring in more than $41 billion to the state over the next 25 years and contribute to the creation of more than 6,800 jobs in Texas."

This announcement builds on a series of significant investments the state has made over the last decade to elevate Texas to the forefront of biotech research and development, beginning in 2005, with the Texas Institute for Genomic Medicine at Texas A&M University. Later, the National Center for Therapeutics Manufacturing was established to create a skilled bio-pharmaceutical workforce proficient in therapeutics manufacturing, he added.

"We are honored to welcome GSK to Texas A&M as a key partner in the Center for Innovation," Chancellor John Sharp said. "GSK's dedication to public service is well-aligned with the Texas A&M tradition of serving the nation and defining its future through research and scholarship. Equally important is the cultural and philosophical match between GSK and the A&M System, as reflected by GSK's desire to collaborate with academia and the U.S. government, and their ongoing commitment to helping address global health scourges such as pandemic influenza and malaria."

RELATED TOPICS AND ARTICLES

Exclusive Research